OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
COVID drug Paxlovid was hailed as a game-changer. What happened?
Max Kozlov
Nature (2023) Vol. 613, Iss. 7943, pp. 224-225
Closed Access | Times Cited: 17
Max Kozlov
Nature (2023) Vol. 613, Iss. 7943, pp. 224-225
Closed Access | Times Cited: 17
Showing 17 citing articles:
Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance
Jonathan Daniel Ip, Allen Wing‐Ho Chu, Wan-Mui Chan, et al.
EBioMedicine (2023) Vol. 91, pp. 104559-104559
Open Access | Times Cited: 72
Jonathan Daniel Ip, Allen Wing‐Ho Chu, Wan-Mui Chan, et al.
EBioMedicine (2023) Vol. 91, pp. 104559-104559
Open Access | Times Cited: 72
Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial
Anne F. Luetkemeyer, Kara W. Chew, Stuart R. Lacey, et al.
Clinical Infectious Diseases (2025)
Open Access | Times Cited: 1
Anne F. Luetkemeyer, Kara W. Chew, Stuart R. Lacey, et al.
Clinical Infectious Diseases (2025)
Open Access | Times Cited: 1
Relative effectiveness of bivalent COVID-19 vaccine: a systematic review and meta-analysis
Meng-qun Cheng, Rong Li, Zhiying Weng, et al.
Frontiers in Medicine (2024) Vol. 10
Open Access | Times Cited: 5
Meng-qun Cheng, Rong Li, Zhiying Weng, et al.
Frontiers in Medicine (2024) Vol. 10
Open Access | Times Cited: 5
Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19–Related Hospitalization and Mortality: A Systematic Literature Review
A. Cha-Silva, M. Gavaghan, Tobias Bergroth, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 3, pp. e246-e257
Open Access | Times Cited: 5
A. Cha-Silva, M. Gavaghan, Tobias Bergroth, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 3, pp. e246-e257
Open Access | Times Cited: 5
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — United States and International Sites, 2021–2022
Patrick R. Harrington, Jie Cong, Stephanie B. Troy, et al.
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 51, pp. 1365-1370
Open Access | Times Cited: 13
Patrick R. Harrington, Jie Cong, Stephanie B. Troy, et al.
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 51, pp. 1365-1370
Open Access | Times Cited: 13
Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir for COVID-19 Among Individuals at High Risk: A Modeling Study
Emma Birnie, Magda Vergouwe, Brent Appelman, et al.
Open Forum Infectious Diseases (2025) Vol. 12, Iss. 4
Open Access
Emma Birnie, Magda Vergouwe, Brent Appelman, et al.
Open Forum Infectious Diseases (2025) Vol. 12, Iss. 4
Open Access
FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms
Mahmoud Ahmed, Ayman Farag, Ian N. Boys, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114614-114614
Open Access | Times Cited: 8
Mahmoud Ahmed, Ayman Farag, Ian N. Boys, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114614-114614
Open Access | Times Cited: 8
Chrysin 7-O-β-D-glucuronide, a dual inhibitor of SARS-CoV-2 3CLpro and PLpro, for the prevention and treatment of COVID-19
Yi Yang, Rong Yu, Heng Xue, et al.
International Journal of Antimicrobial Agents (2023) Vol. 63, Iss. 1, pp. 107039-107039
Open Access | Times Cited: 6
Yi Yang, Rong Yu, Heng Xue, et al.
International Journal of Antimicrobial Agents (2023) Vol. 63, Iss. 1, pp. 107039-107039
Open Access | Times Cited: 6
The Next Generation COVID‐19 Antiviral; Niclosamide‐Based Inorganic Nanohybrid System Kills SARS‐CoV‐2
Goeun Choi, N. Sanoj Rejinold, Huiyan Piao, et al.
Small (2023)
Closed Access | Times Cited: 5
Goeun Choi, N. Sanoj Rejinold, Huiyan Piao, et al.
Small (2023)
Closed Access | Times Cited: 5
SARS-CoV-2: The Virus, Its Biology and COVID-19 Disease-Counteracting Possibilities
Rolf Marschalek
Frontiers in Bioscience-Landmark (2023) Vol. 28, Iss. 10
Open Access | Times Cited: 4
Rolf Marschalek
Frontiers in Bioscience-Landmark (2023) Vol. 28, Iss. 10
Open Access | Times Cited: 4
Difluorocarbene-enabled synthesis of 18F-radiotracers in positron emission tomography
Xiaohui Liu, Chunyang Huan, Xiaofeng Zhang, et al.
Journal of Fluorine Chemistry (2024) Vol. 274, pp. 110253-110253
Closed Access | Times Cited: 1
Xiaohui Liu, Chunyang Huan, Xiaofeng Zhang, et al.
Journal of Fluorine Chemistry (2024) Vol. 274, pp. 110253-110253
Closed Access | Times Cited: 1
Viral rebound and safety of nirmatrelvir/ritonavir for lung-transplant recipients infected with SARS-CoV-2
Hui Li, Zhao Li, Ke Huang, et al.
Biosafety and Health (2023) Vol. 5, Iss. 5, pp. 266-271
Open Access | Times Cited: 2
Hui Li, Zhao Li, Ke Huang, et al.
Biosafety and Health (2023) Vol. 5, Iss. 5, pp. 266-271
Open Access | Times Cited: 2
Insights from a community-based survey on factors influencing acceptance and uptake of Paxlovid (nirmatrelvir and ritonavir) as a COVID-19 antiviral medication in Singapore
Sheng En Alexius Matthias Soh, Wei Ling Brenda Ong, Tun-Linn Thein, et al.
BMC Public Health (2024) Vol. 24, Iss. 1
Open Access
Sheng En Alexius Matthias Soh, Wei Ling Brenda Ong, Tun-Linn Thein, et al.
BMC Public Health (2024) Vol. 24, Iss. 1
Open Access
The problem of SARS-CoV-2 virus resistance to direct-acting antivirals
Е. Л. Гасич, Е. Н. Кроткова, A. D. Kasko, et al.
Biological Products Prevention Diagnosis Treatment (2024)
Open Access
Е. Л. Гасич, Е. Н. Кроткова, A. D. Kasko, et al.
Biological Products Prevention Diagnosis Treatment (2024)
Open Access
Blood Disorders: Response and Achille Heel in the Framework of SARS-Cov-2- a Short Review
Maria Giovanna Buonomenna
Elsevier eBooks (2024), pp. 455-466
Closed Access
Maria Giovanna Buonomenna
Elsevier eBooks (2024), pp. 455-466
Closed Access
A theory for viral rebound after antiviral treatment: A study case for SARS-CoV-2
Mara Pérez, Marcelo Actis, Ignacio José García Sánchez, et al.
Mathematical Biosciences (2024), pp. 109339-109339
Closed Access
Mara Pérez, Marcelo Actis, Ignacio José García Sánchez, et al.
Mathematical Biosciences (2024), pp. 109339-109339
Closed Access
Mitigating COVID-19 Mortality and Morbidity in China's Aging Population: A Focus on Available Medications and Future Developments
Evelyne Bischof
Aging and Disease (2023) Vol. 14, Iss. 6, pp. 1967-1967
Open Access
Evelyne Bischof
Aging and Disease (2023) Vol. 14, Iss. 6, pp. 1967-1967
Open Access
